Introduction {#s1}
============

Dilated cardiomyopathy (DCM), which is characterized by ventricular chamber enlargement and systolic dysfunction with normal left ventricular wall thickness, leads to progressive heart failure, arrhythmias, and sudden or heart failure related death. Previous family studies revealed that 20% to 50% of idiopathic DCM had a familial origin, suggesting genetic factors might play an important role in the disease pathogenesis. [@pone.0063309-Michels1] On the other side, hypertrophic cardiomyopathy (HCM), which is diagnosed in the presence of left ventricular hypetrophy, is also reported to be genetically heterogenous. [@pone.0063309-Kaufman1] During the past two decades, several genetic mutations were reported to cause DCM or HCM.

Several genes encoding the components of the renin-angiotensin-aldosterone system (RAAS) have been revealed to be associated with cardiovascular diseases, including hypertension, myocardial infarction, ischemic stroke, and cardiomyopathy. [@pone.0063309-Zhang1], [@pone.0063309-Zhang2], [@pone.0063309-OrenesPinero1] As DCM to be considered, the insertion/deletion polymorphism in the angiotensin I converting enzyme gene (ACE I/D) has been commonly reported. [@pone.0063309-Raynolds1], [@pone.0063309-Montgomery1] However, the previous results were inconsistent. Raynolds MV et al found that compared with the DD frequency in the control population, the frequency of the ACE DD genotype was 48% higher in individuals with idiopathic DCM. [@pone.0063309-Raynolds1] However, Montgomery HE et al reported that the ACE genotype distribution and allele frequencies were similar in patients and control subjects. [@pone.0063309-Montgomery1] Furthermore, current evidence supported the inhibition of renin-angiotensin system might be beneficial to patients of DCM. Similarly, the association between ACE I/D polymorphisms and HCM was also inconsistently reported [@pone.0063309-Kaya1], [@pone.0063309-Yamada1].

To date, no large-scale studies have assessed the association between ACE I/D polymorphisms and DCM or HCM. This lack of knowledge emphasizes the importance of the present meta-analysis. Thus, we performed this meta-analysis to clarify this inconsistency between ACE I/D polymorphisms and DCM or HCM.

Materials and Methods {#s2}
=====================

A computerized search of PubMed and the Cochrane Library published before November 2012 was conducted. Only studies published in English were considered. Furthermore, the references of the relevant studies were also searched. The google scholar website was also searched. When the same patient population was included in different reports, only the study with complete data was used in this meta-analysis. We used the following key words for searching for the relevant reports: angiotensin I converting enzyme, dilated cardiomyopathy, hypertrophic cardiomyopathy, variant and polymorphism. Two reviewers (J.M Yang and C Zhang) independently searched the titles, abstracts, and full-texts to determine whether the data met the inclusion criteria. Conflicts were resolved by consensus.

Inclusion Criteria {#s2a}
------------------

The studies included in the meta-analysis must meet all the following three criteria: (1) evaluating the association of ACE I/D polymorphism with DCM or HCM; (2) using case-control design; (3) providing sufficient data upon genotype counts.

Exclusion Criteria {#s2b}
------------------

All the patients were excluded for ischemic cardiomyopathy and severe coronary obstruction for DCM, and potential stimulus such as hypertension, ischemic ischemic heart disease, valvular heart disease, congenital malformations of the heart or vessels, and intrinsic pulmonary disease for HCM.

Data Extraction {#s2c}
---------------

For each study, the following information was extracted: the first author's name, publication date, region and ethnicity of participants, sample size of cases and controls, source of controls, myocardial biopsy, genotype distribution in cases and controls.

Statistical Methods {#s2d}
-------------------

All the statistical analyses were performed by Review Manager version 5.1. Crude odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the association strength between ACE I/D polymorphism and DCM or HCM risk. We also tested the heterogeneity among the included reports and *P*\<0.10 was considered to be significant heterogeneity. In this study, a random effects model was used because of the presence of heterogeneity. Because the number of included studies was \<10, we did not assess the publication bias ([www.cochranehandbook.org](http://www.cochranehandbook.org)).

Results {#s3}
=======

Characteristics of the Included Studies {#s3a}
---------------------------------------

A total of 316 studies were screened and 299 studies were excluded after reading titles and abstracts. One study by Harn HJ et al. was excluded because of lacking full-text. For the two overlapping studies, [@pone.0063309-Yoneya1], [@pone.0063309-Kawaguchi1] the one published recently was included. [@pone.0063309-Kawaguchi1] Two studies investigated the effect of ACE I/D polymorphisms on both DCM and HCM. [@pone.0063309-Yamada1], [@pone.0063309-Rai1] Thus, eight studies on DCM (1387 controls and 977 patients, [Table 1](#pone-0063309-t001){ref-type="table"}) and eight studies on HCM (1055 controls and 827 patients, [Table 2](#pone-0063309-t002){ref-type="table"}) were included in this meta-analysis ([Figure 1](#pone-0063309-g001){ref-type="fig"}). [Table 3](#pone-0063309-t003){ref-type="table"} showed the genotype distribution in each included study.

![Flow chart of studies selection.](pone.0063309.g001){#pone-0063309-g001}
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###### The characteristics of eligible studies on DCM considered in the meta-analysis.

![](pone.0063309.t001){#pone-0063309-t001-1}

  Author                                                 Year   Region    Ethnicity   Sample size (case/control)   Source of controls   Myocardialbiopsy                             Diagnostic criteria
  ----------------------------------------------------- ------ --------- ----------- ---------------------------- -------------------- ------------------ -------------------------------------------------------------------------
  Raynolds MV et al. [@pone.0063309-Raynolds1]           1993     USA     Caucasian             112/79               Healthy donors           Yes                   EF\<40%, LV enlargement and normal coronary arteries
  Montgomery HE et al. [@pone.0063309-Montgomery1]       1995   England    English              99/364              Healthy subjects          Yes                     EF\<40%, LV dilation and normal coronary arteries
  Sanderson JE et al. [@pone.0063309-Sanderson1]         1996    China     Chinese             100/100              Healthy subjects          Yes          EF\<40%, fractional shortening\<25% and with no ischemic cardiomyopathy
  Yamada Y et al. [@pone.0063309-Yamada1]                1997    Japan    Japanese              88/122              Healthy subjects          Yes                           DCM without other potential stimulus
  Tiret L et al. [@pone.0063309-Tiret1]                  2000   French       NA                422/387              Healthy subjects           No                 EF\<40%, LV dilation and with no ≥50% artery obstruction
  Rai TS et al. [@pone.0063309-Rai1]                     2008    India     Indian               51/164              Healthy subjects           No                EF\<40% and LV end diastolic diameter\>117% of normal value
  Kucukarabaci B et al. [@pone.0063309-Kucukarabaci1]    2008   Turkey     Turkish              29/20               Healthy subjects           No                                            NA
  Mahjoub S et al. [@pone.0063309-Mahjoub1]              2010   Tunisia   Tunisian              76/151              Healthy subjects           No                 LV fractional shortening \<25%, EF\<45% and LVEDD\>69 mm

DCM, dilated cardiomyopathy; NA, not available; EF, ejection fraction; LV, left ventricular.

10.1371/journal.pone.0063309.t002

###### The characteristics of eligible studies on HCM considered in the meta-analysis.

![](pone.0063309.t002){#pone-0063309-t002-2}

  Author                                           Year   Region   Ethnicity   Sample size (case/control)      Source of controls       Myocardialbiopsy                                    Diagnostic criteria
  ----------------------------------------------- ------ -------- ----------- ---------------------------- --------------------------- ------------------ ---------------------------------------------------------------------------------------
  Marian AJ et al. [@pone.0063309-Marian1]         1993    USA        NA                100/106             Familiar healthy subjects          No                  septal or ventricular thickness≥13 mm without other potential causes
  Pfeufer A et al. [@pone.0063309-Pfeufer1]        1996   German   Caucasian             50/50                  Healthy subjects               No          septal or ventricular thickness≥13 mm without hypertension and valvular heart disease
  Yamada Y et al. [@pone.0063309-Yamada1]          1997   Japan    Japanese              71/122                 Healthy subjects              Yes                              LV hypertrophy without other potential causes
  Ogimoto A et al. [@pone.0063309-Ogimoto1]        2002   Japan    Japanese             138/205                 Healthy subjects               No                              LV hypertrophy without other potential causes
  Kawaguchi H et al. [@pone.0063309-Kawaguchi1]    2003   Japan    Japanese              80/88              Familiar healthy subjects          No                              LV hypertrophy without other potential causes
  Rai TS et al. [@pone.0063309-Rai1]               2008   India     Indian              118/164                 Healthy subjects               No                      Unexplained LV hypertrophy ≥13 mm or \>2 standard deviations
  Kaya CT et al. [@pone.0063309-Kaya1]             2010   Turkey    Turkish              63/20                  Healthy subjects               No                        LV hypertrophy ≥13 mm without other hypertrophic stimulus
  Coto E et al. [@pone.0063309-Coto1]              2010   Spain    Caucasian            207/300                 Healthy subjects               No                        LV hypertrophy ≥13 mm without other hypertrophic stimulus

HCM, hypertrophic cardiomyopathy; NA, not available; LV, left ventricular.

10.1371/journal.pone.0063309.t003

###### The distribution of polymorphism for cases and controls.

![](pone.0063309.t003){#pone-0063309-t003-3}

                                                                      Genotypes (n)   Alleles (n)                                           
  ----- ----------------------------------------------------- ------ --------------- ------------- ----- ---- ----- ----- ----- ----- ----- -----
            Raynolds MV et al. [@pone.0063309-Raynolds1]       1993        72             40        60    19   NA    NA    NA    NA         
          Montgomery HE et al. [@pone.0063309-Montgomery1]     1995        18             50        31    84   168   112   86    334   112   292
           Sanderson JE et al. [@pone.0063309-Sanderson1]      1996        39             49        12    39   48    13    127   126   73    74
               Yamada Y et al. [@pone.0063309-Yamada1]         1997        36             35        17    50   55    17    107   155   69    89
                Tiret L et al. [@pone.0063309-Tiret1]          2000        94             200       128   71   190   126   388   332   456   442
                 Rai TS et al. [@pone.0063309-Rai1]            2008         8             33        10    47   87    30    49    181   53    147
         Kucukarabaci B et al. [@pone.0063309-Kucukarabaci1]   2008         5             18         6    7     9     4    28    23    30    17
              Mahjoub S et al. [@pone.0063309-Mahjoub1]        2010        12             38        26    46   83    22    62    175   90    127
  HCM                                                                                                                                       
              Marian AJ et al. [@pone.0063309-Marian1]         1993         7             49        44    22   46    38    63    90    137   122
              Pfeufer A et al. [@pone.0063309-Pfeufer1]        1996        26             24        36    14   NA    NA    NA    NA         
               Yamada Y et al. [@pone.0063309-Yamada1]         1997        31             32         8    50   55    17    94    155   48    89
              Ogimoto A et al. [@pone.0063309-Ogimoto1]        2002        53             64        21    83   95    27    170   261   106   149
            Kawaguchi H et al. [@pone.0063309-Kawaguchi1]      2003        26             41        13    43   28    17    93    114   67    62
                 Rai TS et al. [@pone.0063309-Rai1]            2008        11             63        44    47   87    30    85    181   151   147
                Kaya CT et al. [@pone.0063309-Kaya1]           2010         8             34        21    5     9     6    50    19    76    21
                 Coto E et al. [@pone.0063309-Coto1]           2010        35             100       72    46   135   119   170   227   242   373

DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; NA, not available.

Association of ACE I/D Polymorphisms and DCM Susceptibility {#s3b}
-----------------------------------------------------------

Although the overall results demonstrated that the D allele carriers might be more susceptible to DCM, the risk did not reach a statistical significance. (DD/ID vs. II: OR = 1.34, 95% CI 0.92--1.95, *P* = 0.13; DD vs. ID/II: OR = 1.27, 95% CI 0.93--1.74, *P* = 0.13; DD vs. II: OR = 1.44, 95% CI 0.88--2.36, *P* = 0.14). Similarly, in the subgroup analysis by ethnicity, no significantly increased risk was found for D allele carriers among East Asians and Europeans. ([Table 4](#pone-0063309-t004){ref-type="table"}).

10.1371/journal.pone.0063309.t004

###### Summary of pooled ORs according to ACE I/D polymorphisms.

![](pone.0063309.t004){#pone-0063309-t004-4}

                                       DCM                HCM                                               
  ----------------------------- ------------------ ------------------ ------------------ ------------------ ------------------
  **2/2 versus 1/1**                                                                                        
  OR(95% CI)                     1.44(0.88--2.36)   1.16(0.64--2.11)   0.93(0.57--1.53)   1.67(0.90--3.11)   1.10(0.69--1.74)
  *P* value for heterogeneity          0.01               0.51               0.18              0.0006              0.68
  **2/2 versus 1/1+1/2**                                                                                    
  OR(95% CI)                     1.27(0.93--1.74)   1.20(0.69--2.08)   1.02(0.81--1.29)   1.27(0.88--1.82)   0.96(0.63--1.48)
  *P* value for heterogeneity          0.06               0.40               0.18               0.02               0.67
  **2/2+1/2 versus 1/1**                                                                                    
  OR(95% CI)                     1.34(0.92--1.95)   1.00(0.67--1.49)   0.91(0.68--1.22)   1.69(1.04--2.74)   1.20(0.88--1.63)
  *P* value for heterogeneity          0.02               0.99               0.11              0.0009              0.17
  **1/2 versus 1/1**                                                                                        
  OR(95% CI)                     1.10(0.88--1.37)   0.95(0.62--1.45)   0.93(0.68--1.27)   1.62(1.06--2.46)   1.29(0.76--2.20)
  *P* value for heterogeneity          0.12               0.74               0.12               0.01               0.09
  **2/2 versus 1/2**                                                                                        
  OR(95% CI)                     1.08(0.87--1.35)   1.22(0.68--2.20)   0.96(0.73--1.25)   0.99(0.79--1.26)   0.85(0.54--1.34)
  *P* value for heterogeneity          0.20               0.36               0.90               0.26               0.36

ACE, angiotensin I converting enzyme; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy;

1/1, homozygosity for I allele; 1/2, heterozygosity; 2/2, homozygosity for D allele; CI, confidence interval; OR, odds ratio.

Association of ACE I/D Polymorphisms and HCM Susceptibility {#s3c}
-----------------------------------------------------------

Overall, compared with ACE II genotype, patients with D allele showed a significant increased risk of HCM (DD/ID vs. II: OR = 1.69, 95% CI 1.04--2.74, *P* = 0.03). However, patients with DD genotype did not showed significant risk of HCM compared with II genotype (DD vs. II: OR = 1.67, 95% CI 0.90--3.11, *P* = 0.10) or I allele carriers (DD vs. ID/II: OR = 1.27, 95% CI 0.88--1.82, *P* = 0.20). In the subgroup analysis by ethnicity, no statistically increased risk was found for D allele carriers among Japanese. ([Table 4](#pone-0063309-t004){ref-type="table"}).

Discussion {#s4}
==========

To our best knowledge, our present study is the first meta-analysis to assess the association between ACE I/D polymorphism and DCM or HCM risk. Overall, our meta-analysis suggested that ACE I/D polymorphisms might be associated with HCM susceptibility but not DCM.

The angiotensin I converting enzyme enhances the synthesis of angiotensin II (Ang II), which induces cell proliferation, migration and hypertrophy, and enhances the proinflammatory cytokines and matrix metalloproteinases. Thus, overexpression of Ang II plays a powerful role in cardiomyopathy. Studies have demonstrated blocking Ang II is beneficial to patients with cardiomyopathy or heart failure. Previous studies have found that ACE I/D polymorphisms are related with plasma Ang II levels. ACE I/D polymorphisms have been extensively examined for a variety of clinical endpoints, such as hypertension, coronary artery disease [@pone.0063309-Kato1], cough [@pone.0063309-Nishio1] and cancer [@pone.0063309-Sun1]. The ACE I/D polymorphisms also modulate the phenotype in patients with DCM and HCM. However, studies from different populations have demonstrated conflicting data. Mahjoub S et al. found that DD genotype and D allele of angiotensin-converting enzyme I/D gene polymorphism are associated with increased risk of dilated cardiomyopathy in a Tunisian population, [@pone.0063309-Mahjoub1] while Tiret L et al did not find this correlation. [@pone.0063309-Tiret1] In the present meta-analysis, our overall results did not show significant association between ACE I/D polymorphisms and DCM risk. Furthermore, the subgroup analysis also did not find a statistically increased risk in D allele carriers among East Asians and Europeans, suggesting ACE I/D polymorphisms might not be associated with DCM risk. The previous data of ACE I/D polymorphisms in HCM patients also did not reach a consistency. Rai TS et al found that D allele of ACE I/D polymorphism significantly influences the HCM phenotypes. [@pone.0063309-Rai1] However, Yamada Y et al reported that the ACE I/D polymorphisms are not related to HCM in a Japanese population. [@pone.0063309-Yamada1] Our current meta-analysis found that compared with ACE II genotype, patients with D allele showed a significant increased risk of HCM, suggesting ACE I/D polymorphisms might attribute to HCM risk.

Several limitations should be considered. First, some genetic defects were known in HCM or DCM. However, all the included studies did not present such information, which might affect the analysis results. Second, heterogeneity among the included studies may affect the interpretation of the results of the meta-analysis. Third, most of the sample sizes of the referenced studies are relatively small, which might weaken the meta-analysis results. Furthermore, lamin A/C mutations in DCM and sarcomeric mutations in HCM contribute a lot to cardiomyopathy risk. [@pone.0063309-Malhotra1] The study by Coto E et al found a possible association between AT1R A1166C but not ACE I/D polymorphisms and HCM. [@pone.0063309-Coto1] Unfortunately, little was known about the role of ACE I/D polymorphisms in lamin A/C and sarcomeric mutations risk. Further study is needed to confirm this association.

Overall, the present meta-analysis suggested that certain ACE I/D polymorphism might be associated with HCM but not DCM susceptibility. The findings of the current study may add benefit to risk stratification strategies in patients with HCM and may encourage further study focusing on the effect of ACE I/D polymorphisms on HCM and risk. These results also suggest a potential treatment approach by regulating RASS in HCM patients. However, given the small sample sizes in this meta-analysis, further large random case-control studies are needed for further confirmation.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: Conceived and designed the experiments: YZ CZ JMY. Performed the experiments: YZ CZ YHZ JMY PPH XM MD YW. Analyzed the data: PPH CZ JMY YHZ. Contributed reagents/materials/analysis tools: CZ. Wrote the paper: YZ CZ JMY.
